KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Change in Acquisitions & Divestments (2016 - 2026)

Bristol Myers Squibb has reported Change in Acquisitions & Divestments over the past 18 years, most recently at $391.0 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments rose 77.73% to $391.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Mar 2026, up 260.67% year-over-year, with the annual reading at $2.0 billion for FY2025, 76.02% up from the prior year.
  • Change in Acquisitions & Divestments was $391.0 million for Q1 2026 at Bristol Myers Squibb, down from $402.0 million in the prior quarter.
  • Over five years, Change in Acquisitions & Divestments peaked at $5.1 billion in Q3 2022 and troughed at -$762.0 million in Q3 2024.
  • The 5-year median for Change in Acquisitions & Divestments is $391.0 million (2026), against an average of $625.4 million.
  • Year-over-year, Change in Acquisitions & Divestments surged 2750.0% in 2023 and then tumbled 221.92% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $1.2 billion in 2022, then crashed by 96.6% to $41.0 million in 2023, then skyrocketed by 2490.24% to $1.1 billion in 2024, then plummeted by 62.15% to $402.0 million in 2025, then dropped by 2.74% to $391.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Change in Acquisitions & Divestments are $391.0 million (Q1 2026), $402.0 million (Q4 2025), and $829.0 million (Q3 2025).